Ben Teh Tori Hall Great work Tori! 2 doses of adjuvanted flu vaccine bring more side effects for no benefit compared to 2 standard doses of fluvax in patients with haem malignancy. Important findings!

#ECCMID2024 Results from RCT of SD vs AD flu vaccine as a strategy for high-risk HM group by Tori Hall NCIC Ben Teh showing no difference in primary outcome seroconversion but highlighting the CLL NHL groups as having poor responses in general. How to improve this?

Hot off the press - late breaking data from Tori Hall NCIC demonstrating similiar immunogenicity from two different vax strategies and no incremental benefit of second dose. #ESCMIDGlobal2024 #TxID

An amazing nation wide randomised trial of a simple reminder transforming vaccination uptake, even in immune compromised. Elegant solution. #ESCMIDGlobal2024 #TxID

Aussies living in 🇦🇺and 🇨🇦 bonding in 🇪🇸over our favourite topic of coffee! Tori Hall

True Aussies 🇦🇺 sourcing out Melbourne roasted coffee ☕️ ESCMID NCIC Michelle Yong

Happy to meet my Toronto colleagues Tori Hall atul humar at #ECCMID2024 to share our data about COVID-19 in SOT

A full house at Ben Teh #ECCMID2024 ESCMID discussing vaccine strategies. We aren’t doing as well as we think. Complex schedules, lack of clarity in responsibilities and access to info. Some principles and strategies to implement…NCIC Tori Hall

Congratulations Ben Teh for a tour de force on vaccination strategies and increasing uptake in immunocompromised patients - a full house in Hall C! NCIC ESCMID

Ben Teh reviews the drivers for really poor vaccination among immunocompromised patients - interventions that can reduce the morbidity and mortality of common infections - key is to do better ECCMID ESCMID

Excited to see this important study being started by ESGREV - reach out to [email protected] if you want to join

Great Start
with ESGICH #eccmid2024

Looking forward to the next 4 days #ECCMID2024 ! Here are some of the sessions from NCIC that may be of interest….. #TID monica slavin NCAS_Australia Tori Hall Ben Teh

Aztreonam-avibactam approved in Europe. Will be a welcome addition to our armamentarium against MBLs. investors.pfizer.com/Investors/News…

'Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023' by Solera et al

doi.org/10.1016/j.ajt.…

Javier T. Solera Tori Hall Deepali Kumar atul humar Aman Sidhu Nazia Selzner Ajmera Transplant Centre UHN

We are so excited that Nature Communications has selected our recent publication as a featured article for the Microbiology and Infectious Diseases Editor's Highlights. Isabelle Foo Katherine Kedzierska Lukasz

nature.com/collections/je…

nature.com/articles/s4146…

ESGICH (the ESCMID Study Group for Infections in Compromised Host) is awarding 4 trainee and young investigators awards. Congratulations!!

Congratulations to Tori Hall who will presenting in Hall C on 29 April 11am-12pm.